Mayo Clinic Cancer Center announced that it is participating in an expanded access program for the experimental cancer drug MK-3475 at its three sites in Arizona, Florida and Minnesota. MK-3475 is a therapy for the treatment of metastatic melanoma. This program will provide expanded access to the drug prior to its approval by the Food and Drug Administration (FDA).
The expanded access program for MK-3475 is available at Mayo Clinic Cancer Center sites in Arizona, Florida and Minnesota. For more information, call 507-538-7623